Importantly, the recent approval of trastuzumab deruxtecan for HER2-mutant NSCLC was primarily based on mutational status rather than protein expression levels, but new emerging data may suggest response to HER2 expressed tumors. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.